Clinical AdvancementsOV350 is the first candidate emerging from Ovid’s novel portfolio of KCC2 direct activators, exhibiting 100-1,000-fold higher potency for KCC2 compared to other peripheral K/Cs and NKCC1, limiting peripheral side effects.
Pipeline DevelopmentOvid Therapeutics has reprioritized its pipeline development efforts to focus more on the earlier-stage assets OV329 and OV350, while also preparing for the entry into the clinic of another candidate, OV4071.